DDInter1255 DDInter1676
Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adverse effects. Nadolol was granted FDA approval on 10 December 1979.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Nadolol {u} (Compound) resembles {v} (Compound) Carteolol
Nadolol {u} (Compound) treats {v} (Disease) hypertension
Nadolol {u} (Compound) binds {v} (Gene) ABCB1
Nadolol {u} (Compound) upregulates {v} (Gene) EVL
Nadolol {u} (Compound) downregulates {v} (Gene) CSRP1
Nadolol {u} (Compound) causes {v} (Side Effect) Body temperature increased
Nadolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magaldrate
Nadolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Liothyronine
Nadolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Scopolamine
Nadolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pasireotide
Nadolol (Compound) resembles Carteolol (Compound)
Nadolol (Compound) treats hypertension (Disease)
Nadolol (Compound) binds ABCB1 (Gene)
Nadolol (Compound) upregulates EVL (Gene)
Nadolol (Compound) downregulates CSRP1 (Gene)
Nadolol (Compound) causes Body temperature increased (Side Effect)
Nadolol may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Nadolol may cause a minor interaction that can limit clinical effects when taken with Liothyronine
Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine
Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide